International Clinical Trial: A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)

Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07124078) titled 'A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)' on Aug. 8.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Incyte Corporation

Condition: Chronic Graft-versus-host-disease

Intervention: Drug: INCA034176

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: December 15, 2025

Target Sample Size: 60

To know more, visit...